3/28/2014 7:45:43 AM
MannKind Corp. (MNKD:US)’s inhaled diabetes drug, found to be effective against Type 2 diabetes, is linked to potential breathing problems that may limit its use in patients with lung diseases, U.S. regulators said . MannKind’s Afrezza, a powdered form of insulin delivered through an inhaler, would be the company’s first marketed drug, if approved. A Food and Drug Administration staff report today tied the product to a decline in lung function, bronchial spasms similar to asthma and coughing that caused some patients in trials to stop treatment, according to an online document.
Help employers find you! Check out all the jobs and post your resume.
comments powered by